This paper looks at how well the medication upadacitinib (combined with topical steroids) helps improve quality of life and symptoms like itching in people with atopic dermatitis. The study followed patients for 52 weeks to see how the treatment affected their daily life, sleep, emotional state, and other patient-reported outcomes.
-
Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study.
Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study.
Nina Magnolo, Michael C Cameron, Mona Shahriari, Bob Geng, Brian M Calimlim, Henrique Teixeira, Xiaofei Hu, Yang Yang, Yingyi Liu, Shiyu Zhang, Cristina Sancho Sanchez, Katherine Altman, Richard G Langley
DOI: 10.1080/09546634.2024.2344589
Controlled Clinical Trial
•
901 participants
•
2024
•
0 citations
Key insights related to Rinvoq from this study:
-
What is this paper about?
-
How did the authors study this?
The researchers conducted a phase 3 clinical trial called AD Up where they randomly assigned patients to receive either upadacitinib (15mg or 30mg daily) plus topical steroids or a placebo plus topical steroids. They measured various aspects of patients' experiences including itch, skin pain, sleep quality, daily activities, and emotional state using standardized questionnaires.
-
What populations did the authors study?
The study included 901 adults and adolescents with moderate-to-severe atopic dermatitis. All participants had significant enough disease to qualify for systemic therapy.
-
What did the authors find?
Both doses of upadacitinib showed better improvements than placebo within 1-2 weeks of starting treatment. By week 52, between 62-78% of patients on the 15mg dose and 71-84% of patients on the 30mg dose showed meaningful improvements in symptoms like itch, skin pain, sleep, daily activities, and emotional state. These improvements started quickly and lasted throughout the study.
-
What conclusions can we draw?
The authors concluded that upadacitinib combined with topical steroids provides quick and long-lasting improvements in bothersome atopic dermatitis symptoms and quality of life. The benefits were maintained over the full year of the study.
Did this article interest you?
As a member of the Lemma Health community, you'll stay up to date with research, hear about new products, and get exclusive access to discounts.
Ready for better skin health?
At Lemma Health, we provide evidence-based skin care. Access dermatologists in all 50 states. Appointments available within 3 days. Receive your medications delivered. Get ongoing 24/7/365 support. Coordinate your care across specialties.